Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
triamcinolone acetonide + 5-fluorouracil
- Development stage
- Unknown
- Lead developer
- University of Washington
- Modality
- Small Molecules
- Administration
- Intralesional, Ophthalmic
01
Overview
This investigational combination therapy, developed and studied by the University of Washington, consists of the antimetabolite 5-fluorouracil (5-FU) and the corticosteroid triamcinolone acetonide. It is specifically designed for the treatment of chalazia (eyelid cysts) and is administered via local intralesional injection directly into the lesion. The combination typically utilizes a 9:1 ratio of 5-FU to triamcinolone acetonide. 5-FU acts as a chemotherapy agent that inhibits thymidylate synthase, thereby disrupting DNA synthesis in the proliferating cells of the chalazion, while triamcinolone acetonide provides potent anti-inflammatory effects. This dual mechanism aims to reduce the size of the chalazion and improve cosmetic appearance while minimizing the side effects associated with high-dose steroid injections, such as skin hypopigmentation and increased intraocular pressure.
- Other names
- triamcinolone acetonide/5-fluorouracil mixture5-fluorouracil/triamcinolone acetonide mixturetriamcinolone/5-FU mixture
02
Targets
GR (Glucocorticoid receptor)TS (Thymidylate synthase)
Beyond the preview
Go deeper on triamcinolone acetonide + 5-fluorouracil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on triamcinolone acetonide + 5-fluorouracil.